Two years in, Hong Kong’s biotech experiment has been validated
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.
On April 30th, the two-year anniversary passed of the Stock Exchange of Hong Kong’s (HKEX) implementation of its new biotech chapter. As we reflect on it two years later, this pivotal decision has aged well with time and is delivering on its promise in a big way. While casual observers might recall that the new biotech era in Hong Kong started off with some growing pains, listings have strengthened over time to the extent that Hong Kong is right up there with New York and is arguably even the stronger market for biotech listings in early 2020. The timing couldn’t have been better. Just as current events illustrate how vital our industry is to the world, biotech is starting to bloom in Asia. This wouldn’t be possible without the public markets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.